 Study E7389-E044-112 is a Phase 1 study designed to assess the safety, tolerability and preliminary efficacy of E7389 liposomal formulation E7389-LF in patients with solid tumors. This dose-escalation study will determine the maximum tolerated dose, dosing schedules tested, the dose schedule regimen with a more favorable tolerability profile, and a preliminary indication of efficacy. 